Get the Stockscreener App
0.0021
0.00%
0.00
Nkgen Biotech Inc stock is traded at $0.0021, with a volume of 8,118.
It is up +0.00% in the last 24 hours and down -58.82% over the past month.
See More
Previous Close:
$0.0021
Open:
$0.011
24h Volume:
8,118
Relative Volume:
0.91
Market Cap:
$N/A
Revenue:
$3,000
Net Income/Loss:
$-23.55M
P/E Ratio:
-0.00172
EPS:
-1.2183
Net Cash Flow:
$-19.75M
1W Performance:
+0.00%
1M Performance:
-58.82%
6M Performance:
-96.50%
1Y Performance:
-98.42%
1-Day Range:
$0.0021
$0.011
1-Week Range:
$0.0021
$0.011
52-Week Range:
$0.0003
$0.16
Nkgen Biotech Inc Stock (NKGN) Company Profile
Compare NKGN vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.0021 | 0 | 3,000 | -23.55M | -19.75M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nkgen Biotech Inc Stock (NKGN) Latest News
NKGen Biotech to Present on Troculeucel for - GlobeNewswire
NKGen Biotech to Present on Potential of Troculeucel in - GlobeNewswire
NKGen Biotech Expands Financing Through Convertible Note Issuance - TipRanks
NKGen Biotech Korea Co., Ltd. Revenue Breakdown – KRX:182400 - TradingView
NKGen Biotech Inc. Revenue Breakdown – OTC:NKGNW - TradingView
NKGen Biotech Inc. Revenue Breakdown – OTC:NKGN - TradingView
Price to earnings forward of NKGen Biotech Inc. – OTC:NKGN - TradingView
Price to sales forward of NKGen Biotech Inc. – OTC:NKGN - TradingView
Enterprise value to revenue forward of NKGen Biotech Inc. – OTC:NKGN - TradingView
Price to book forward of NKGen Biotech Inc. – OTC:NKGN - TradingView
NKGen Biotech Amends Term Loan and Collateral Agreement - TipRanks
NKGen Biotech (NKGN) alters collateral on $5M credit facility - Stock Titan
Enterprise value to revenue forward of NKGen Biotech Inc. – OTC:NKGNW - TradingView
Price to book forward of NKGen Biotech Inc. – OTC:NKGNW - TradingView
Price to earnings forward of NKGen Biotech Inc. – OTC:NKGNW - TradingView
Number of employees of NKGen Biotech Inc. – OTC:NKGNW - TradingView
Price to sales forward of NKGen Biotech Korea Co., Ltd. – KRX:182400 - TradingView
NKGen Biotech takes Alzheimer’s research global - Longevity.Technology
Price to earnings forward of NKGen Biotech Korea Co., Ltd. – KRX:182400 - TradingView
Enterprise value to revenue forward of NKGen Biotech Korea Co., Ltd. – KRX:182400 - TradingView
NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards - MSN
NKGen Biotech to present Alzheimer’s drug trocu... - Pluang
NKGen's CEO to Present Alzheimer’s Cell Therapy at Seoul Forum - Stock Titan
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum - GlobeNewswire
Alzheimer’s Disease Pipeline Accelerates as 200+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
NKGen Biotech Expands Convertible Financing Through New Agreement - The Globe and Mail
NKGen Biotech (NKGN) takes $2.42M note, lifts consideration shares - Stock Titan
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - PR Newswire
NKGen Biotech Expands Financing Through New Convertible Loan - TipRanks
NKGen Biotech (NKGN) expands AlpineBrook convertible deal with $412.5K note and new warrant - Stock Titan
Nkgen Biotech expands clinical trial site network for Alzheimer’s disease program across US - marketscreener.com
Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US - TradingView
NKGen Biotech Inc. is expanding its Alzheimer’s disease clinical trial site network nationwide across the United States. - Bitget
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment - marketscreener.com
New Alzheimer’s trial sites move NK cell therapy closer to East Coast patients - Stock Titan
NKGen Biotech Expands Clinical Trial Site Network for - GlobeNewswire
Number of shareholders of NKGen Biotech Inc. – OTC:NKGN - TradingView
NKGen Biotech Secures Additional Convertible Financing and Warrants - TipRanks
NKGen Biotech (NKGN) expands dilutive note deal with 12M+ shares, warrant - Stock Titan
NKGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NKGen Biotech Announces Major Convertible Financing and Governance Shift - TipRanks
NKGen Biotech (NKGN) inks $39,922,134.22 secured convertible loan and control rights - Stock Titan
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit - marketscreener.com
NKGen Biotech to Present Troculeucel Mechanism Data in - GlobeNewswire
Former Bio Firm Executive Charged for Insider Trading on Drug Approval Tip - Seoul Economic Daily
NKGen Biotech Reports Combined Phase 1 Troculeucel Data - GlobeNewswire
Troculeucel Linked to Plasma GFAP Changes and Cognitive Measures in Early Alzheimer Disease Studies - NeurologyLive
Troculeucel may boost cognition, new Alzheimer’s data shows - Longevity.Technology
NKGen Biotech to Present Integrated Phase 1 Clinical and - GlobeNewswire
Nkgen Biotech amends loan agreement to secure additional $343,000 funding - Investing.com
Nkgen Biotech Inc Stock (NKGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.82%
Cap:
|
Volume (24h):